Unveiling the Burden of MASLD and Liver Fibrosis in India: Novel Insights from the Phenome India Study into fibrosis without MASLD
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Metabolically–dysfunction–associated steatotic liver disease (MASLD) is rising globally, including in India, yet community-based data remain scarce. We addressed this critical knowledge gap by assessing the prevalence, distribution, and characteristics of MASLD subgroups and fibrosis, leveraging the Phenome India–CSIR Health Cohort Knowledgebase (PI-CHeCK) study.
Methods
In this prospective, nationwide study, we recruited 10267 adults across 37 laboratories of the Council of Industrial Research (CSIR) from 27 Indian cities. Steatosis and fibrosis were assessed by Transient Elastography using Fibroscan, with associated clinical, biochemical, cytokine, anthropometric, and lifestyle data collected. Overall, crude and age-adjusted prevalence rates were estimated in the study population and various subgroups.
Findings
Of the 10267 individuals screened, 7764 were eligible for analysis after exclusions. Among these, 3,712 (47.8%) fulfilled MASLD criteria, corresponding to an age-adjusted prevalence of 36.3%. Significant fibrosis (≥F2) was more frequent in MASLD (6.3% [234 of 3688]) than in cases of cryptogenic fibrosis without MASLD (1.7% [69 of 4027]), corresponding to an age-adjusted prevalence of 4.1% in MASLD. Overall age-adjusted prevalence of significant fibrosis was 2.3% in the entire cohort, which clustered in older adults (>60 years) and in those with diabetes or obesity II, with evidence of regional variation, peaking in Jorhat, Assam. Importantly, fibrosis in participants without MASLD emerged as a distinct subgroup with disproportionately elevated cytokine levels, exceeding those in MASLD with fibrosis, suggesting a cytokine-rich, high-risk phenotype.
Conclusion
In this nationwide Indian cohort, MASLD affected over one-third of participants with a substantial burden of fibrosis. Notably, fibrosis without-MASLD emerged as a cytokine-rich, high-risk phenotype, underscoring an underrecognized dimension of liver disease with major public health implications.
